ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 1789 • ACR Convergence 2020

    Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels

    Michelle Petri1, Jessica Li2 and Daniel Goldman1, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD

    Background/Purpose: Vitamin D is correctly classified as a sterol-hormone rather than a vitamin (Semin Nephrol 1986;6:4-20). It has multiple immunomodulatory effects, as well as cardiovascular…
  • Abstract Number: 0838 • ACR Convergence 2020

    T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis

    Milena Vukelic1, Masataka Umeda1, Andrew Ferretti2, Rhea Bhargava1, Nobuya Yoshida1 and George Tsokos3, 1Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, 2Beth Israel Deaconess Medical Center Harvard Medical School, Boston, 3Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production, immune complex deposition and multisystem involvement.  Calcium/calmodulin-dependent protein kinase type IV…
  • Abstract Number: 0989 • ACR Convergence 2020

    Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial

    Eliza Chakravarty1, Tammy Utset2, Diane Kamen3, Gabriel Contreras4, W. Joseph McCune5, Kenneth Kalunian6, Cynthia Aranow7, Megan Clowse8, Elena Massarotti9, Ellen Goldmuntz10, Jessica Springer10, Lynette Keyes-Elstein11, Bill Barry11, Ashley Pinckney11 and Judith James12, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Chicago, Chicago, IN, 3Medical University of South Carolina, Charleston, SC, 4University of Miami Miller School of Medicine, Miami, 5University of Michigan, Ann Arbor, MI, 6University of California San Diego, La Jolla, CA, 7Feinstein Institutes for Medical Research, Manhasset, NY, 8Duke University, Chapel Hill, NC, 9Brigham and Women's hospital, Boston, MA, 10NIH/NIAID, Rockville, MD, 11Rho, Durham, NC, 12Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy for long term treatment of lupus nephritis and other manifestations of SLE.  However, it is associated…
  • Abstract Number: 1791 • ACR Convergence 2020

    Renal Tubular Complement C9 Deposition Is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis

    Shudan Wang1, Ming Wu2, Luis Chiriboga2, Beatrice Goilav3, Shuwei Wang4, Chaim Putterman5, Daniel Schwartz6, James Pullman6, Anna Broder7 and H. Michael Belmont8, 1Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, 2NYU Langone Health, New York, 3The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 4Morristown Medical Center, Morristown, NJ, 5Albert Einstein College of Medicine, Bronx, NY, 6Montefiore Medical Center, Bronx, NY, 7Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 8New York University, New York, NY

    Background/Purpose: Tubulointerstitial damage in lupus nephritis (LN) is a strong predictor of progression to chronic kidney disease (CKD) and end stage renal disease (ESRD). While…
  • Abstract Number: 0839 • ACR Convergence 2020

    Single-Cell Transcriptomics of Mouse and Human Lupus Nephritis Identifies Conserved Myeloid Populations Across Species

    Paul Hoover1, Michael Peters2, David Lieb3, Rakesh Mishra4, Nir Hacohen2 and Anne Davidson5, 1Brigham and Women's Hospital, Boston, MA, 2Broad Institute, Boston, 3Broad Institute, Boston, MA, 4Feinstein Institute, Manhasset, NY, 5Northwell Health, New York

    Background/Purpose: We recently identified novel immune cell states in the kidneys of lupus nephritis patients (Arazi et al, Nature Immunology 2019). To determine the similarities…
  • Abstract Number: 1125 • ACR Convergence 2020

    Patient Reported Impact of Lupus on Quality of Life

    Beth Schneider1, 1MyHealthTeams, San Francisco, CA

    Background/Purpose: Research was undertaken to better understand how people living with lupus describe its sum total impact on their lives including work, challenges with relationships…
  • Abstract Number: 1793 • ACR Convergence 2020

    Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership

    Kristina Deonaraine1, Philip Carlucci1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21New York University, New York, NY

    Background/Purpose: Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and affects ~60% of patients during the course of their disease, leading…
  • Abstract Number: 0840 • ACR Convergence 2020

    Amelioration of Immune Complex-Mediated Glomerulonephritis via CD6 Modulation

    Samantha Chalmers1, Sayra Garcia1, Leal Herlitz2, Jeanette Ampudia3, Cherie Ng4, Stephen Connelly3 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2Cleveland Clinic, Cleveland, OH, 3Equillium, Inc, San Diego, CA, 4Equillium, Inc, La Jolla, CA

    Background/Purpose: CD6 is a co-stimulatory receptor, predominantly expressed on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen-presenting…
  • Abstract Number: 1441 • ACR Convergence 2020

    Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis

    Richard Furie1, Brad Rovin2, Frédéric Houssiau3, Gabriel Contreras4, Ana Malvar5, Amit Saxena6, Xueqing Yu7, Y K Onno Teng8, Pieter van Paassen9, Ellen M Ginzler10, Diane Kamen11, Mary Oldham12, Damon Bass13, Andre van Maurik14, Mary Beth Welch13, Yulia Green15, Beulah Ji15, Christi Kleoudis16 and David Roth17, 1Northwell Health, Great Neck, NY, 2The Ohio State University, Columbus, 3Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4University of Miami Miller School of Medicine, Miami, 5Organizacion Medica de Investigacion, Buenos Aires, Argentina, 6NYU School of Medicine, New York, 7Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), 8Leiden University Medical Center, Leiden, Netherlands, 9Maastricht University, Academisch Ziekenhuis Maastricht, Maastricht, Netherlands, 10SUNY Downstate Health Sciences University, Brooklyn, 11Medical University of South Carolina, Charleston, SC, 12GlaxoSmithKline, Stevenage, United Kingdom, 13GlaxoSmithKline, Research Triangle Park, 14GlaxoSmithKline, Stevenage, 15GlaxoSmithKline, Uxbridge, 16Parexel (*At the time of study), Durham, 17GlaxoSmithKline, Collegeville

    Background/Purpose: Belimumab (BEL) has demonstrated efficacy in systemic lupus erythematosus (SLE) in 4 positive pivotal trials. This study assessed the efficacy and safety of intravenous…
  • Abstract Number: 1796 • ACR Convergence 2020

    A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment

    Jennifer Davies1, Emil Carlsson1, Angela Midgley1, Eve Smith1, Ian Bruce2, Michael Beresford1 and Christian Hedrich3, 1Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, Liverpool, England, United Kingdom, 2Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: Approximately 30% of patients with adult-onset systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Presence and/or severity of LN are currently assessed by renal…
  • Abstract Number: 0841 • ACR Convergence 2020

    CD6 Modulation Ameliorates Kidney and Skin Disease in a Spontaneous Murine Lupus Model

    Samantha Chalmers1, Sayra Garcia1, Rajalakshmy Ayilam Ramachandran2, Chandra Mohan2, Leal Herlitz3, Dalena Chu4, Jeanette Ampudia4, Cherie Ng5, Stephen Connelly4 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Houston, Houston, TX, 3Cleveland Clinic, Cleveland, OH, 4Equillium, Inc, San Diego, CA, 5Equillium, Inc, La Jolla, CA

    Background/Purpose: T cells are an important contributor to the pathogenesis of SLE and lupus nephritis, and thus present themselves as interesting therapeutic targets. CD6 is…
  • Abstract Number: 1449 • ACR Convergence 2020

    Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement

    Alejandra Maria Patiño-Trives1, Alejandro Ibáñez-Costa2, Carlos Pérez-Sánchez1, Laura Pérez-Sanchez3, Maria Luque-Tevar1, Iván Arias de la Rosa1, María-Carmen Abalos-Aguilera1, Desirée Ruiz-Vilchez4, Pedro Segui5, Mario Espinosa5, Nuria Barbarroja1, Eduardo Collantes4, Justo P. Castaño5, Raul M Luque5, María de los ángeles Aguirre-Zamorano5 and Chary Lopez-Pedrera1, 1Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, 3Hospital Universitario Reina Sofía, Córdoba, Spain, 4Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 5IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba

    Background/Purpose: To identify shared and differential changes in the splicing machinery of immune cells from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome…
  • Abstract Number: 1801 • ACR Convergence 2020

    An Engineered Extracellular Matrix‐rich Decellularized Substrate Based Podocytes Culture System to Study Intracellular Complement Production and Activation

    Abhigyan Satyam1, Maria Tsokos2 and George Tsokos2, 1Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, boston, 2Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

    Background/Purpose: Current technologies do not support long-term cell viability, differentiation and maintenance of podocytes. We developed a biophysical approach, termed macromolecular crowding (MMC), to create…
  • Abstract Number: 055 • 2020 Pediatric Rheumatology Symposium

    Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)

    Sean Donohue 1, Angela Midgley 1, Jennifer Davies 1, Rachael Wright 1, Ian Bruce 2, Michael Beresford 1 and Christian Hedrich1, 1University of Liverpool, Liverpool, United Kingdom, 2The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is a systemic autoimmune/inflammatory disease. Up to 80% of patients develop lupus nephritis (LN) that affects treatment and prognosis(1-3).…
  • Abstract Number: 127 • 2020 Pediatric Rheumatology Symposium

    Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus

    Emily Smitherman1, Rouba Chahine 1, Timothy Beukelman 1, Laura Lewandowski 2, AKM Fazlur Rahman 1, Scott Wenderfer 3, Aimee Hersh 4 and Jeffrey R Curtis 5 for the CARRA investigators, 1University of Alabama at Birmingham, Birmingham, 2NIAMS, NIH, Rockville, 3Section of Nephrology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 4University of Utah Primary Children's Hospital, Salt Lake City, 5University of Alabama at Birmingham, Hoover

    Background/Purpose: Lupus nephritis associated with childhood-onset systemic lupus erythematosus (cSLE) is a significant risk factor for long-term morbidity and mortality, but little is known regarding…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology